Clinical Trial Update: Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot [NA]

View source ↗

Summary

Completed clinical trial assessing safety and efficacy of Neovasculgen (Pl-VEGF165) gene therapy in patients with diabetic foot ulcers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• Neovasculgen (VEGF165 plasmid DNA (pl-VEGF165))

Snippet

Sponsor: Artgen Biotech | Conditions: Ulcers Related to Diabetic Foot Syndrome | NA | Status: COMPLETED